Current status and potential challenges of mesenchymal stem cell-based therapy for malignant gliomas.
Stem Cell Res Ther
; 9(1): 228, 2018 08 24.
Article
in En
| MEDLINE
| ID: mdl-30143053
ABSTRACT
Glioma, which accounts for more than 30% of primary central nervous system tumours, is characterised by symptoms such as headaches, epilepsy, and blurred vision. Glioblastoma multiforme is the most aggressive, malignant, and lethal brain tumour in adults. Even with progressive combination treatment with surgery, radiotherapy, and chemotherapy, the prognosis for glioma patients is still extremely poor. Compared with the poor outcome and slowly developing technologies for surgery and radiotherapy, the application of targeted chemotherapy with a new mechanism has become a research focus in this field.Moreover, targeted therapy is promising for most solid tumours. The tumour-tropic ability of stem cells, including neural stem cells and mesenchymal stem cells, provides an alternative therapeutic approach. Thus, mesenchymal stem cell-based therapy is based on a tumour-selective capacity and has been thought to be an effective anti-tumour option over the past decades. An increasing number of basic studies on mesenchymal stem cell-based therapy for gliomas has yielded complex outcomes.In this review, we summarise the biological characteristics of human mesenchymal stem cells, and the current status and potential challenges of mesenchymal stem cell-based therapy in patients with malignant gliomas.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Brain Neoplasms
/
Combined Modality Therapy
/
Mesenchymal Stem Cell Transplantation
/
Oncolytic Virotherapy
/
Molecular Targeted Therapy
/
Glioma
Type of study:
Prognostic_studies
Limits:
Animals
/
Humans
Language:
En
Journal:
Stem Cell Res Ther
Year:
2018
Document type:
Article